Abstract
The outstanding physio-pathological role played by integrin receptors in living subjects motivates the enormous interest shown by scientists worldwide for this topic. More than twenty years of research has spanned across the structural and functional elucidation of these proteins and over their antagonism-based biomedical applications. The proof-ofconcept stage, aimed at identifying potent inhibitors, covered a decade of studies, and paved the way for a more advanced era of research where these antagonist molecules were thrown into the deep end of applicative studies. This review intends to summarize the major efforts conducted thus far and focuses on the design, synthesis and biomedical applications of cyclic RGD-containing αvβ3 integrin antagonists, in both their small and macromolecular formats. In particular, Chapters 1 and 2 offer a comprehensive outlook on the rational basis for the design of integrin inhibitors, Chapter 3 chronicles the biological and medical applications of monofunctional RGD integrin ligands both in their monomeric and multimeric asset, and Chapter 4 illustrates the potential of RGD-based multifunctional systems in molecular medicine.
Keywords: Integrins, design of RGD ligands, cancer therapy and imaging, targeted drug delivery, multimodality, integrin targeted nanoparticles
Current Medicinal Chemistry
Title: Targeting αvβ3 Integrin: Design and Applications of Mono- and Multifunctional RGD-Based Peptides and Semipeptides
Volume: 17 Issue: 13
Author(s): L. Auzzas, F. Zanardi, L. Battistini, P. Burreddu, P. Carta, G. Rassu, C. Curti and G. Casiraghi
Affiliation:
Keywords: Integrins, design of RGD ligands, cancer therapy and imaging, targeted drug delivery, multimodality, integrin targeted nanoparticles
Abstract: The outstanding physio-pathological role played by integrin receptors in living subjects motivates the enormous interest shown by scientists worldwide for this topic. More than twenty years of research has spanned across the structural and functional elucidation of these proteins and over their antagonism-based biomedical applications. The proof-ofconcept stage, aimed at identifying potent inhibitors, covered a decade of studies, and paved the way for a more advanced era of research where these antagonist molecules were thrown into the deep end of applicative studies. This review intends to summarize the major efforts conducted thus far and focuses on the design, synthesis and biomedical applications of cyclic RGD-containing αvβ3 integrin antagonists, in both their small and macromolecular formats. In particular, Chapters 1 and 2 offer a comprehensive outlook on the rational basis for the design of integrin inhibitors, Chapter 3 chronicles the biological and medical applications of monofunctional RGD integrin ligands both in their monomeric and multimeric asset, and Chapter 4 illustrates the potential of RGD-based multifunctional systems in molecular medicine.
Export Options
About this article
Cite this article as:
Auzzas L., Zanardi F., Battistini L., Burreddu P., Carta P., Rassu G., Curti C. and Casiraghi G., Targeting αvβ3 Integrin: Design and Applications of Mono- and Multifunctional RGD-Based Peptides and Semipeptides, Current Medicinal Chemistry 2010; 17 (13) . https://dx.doi.org/10.2174/092986710790936301
| DOI https://dx.doi.org/10.2174/092986710790936301 |
Print ISSN 0929-8673 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Zinc as an Appetite Stimulator - The Possible Role of Zinc in the Progression of Diseases Such as Cachexia and Sarcopenia
Recent Patents on Food, Nutrition & Agriculture Editorial [Low Grade Inflammation as a Common Pathogenetic Denominator in Age-Related Diseases: Novel Drug Targets for Anti-Ageing Strategies and Successful Ageing Achievement. PART I. (Executive Editors: Calogero Caruso Thea Magrone and Emilio Jirilllo)]
Current Pharmaceutical Design APO2L/TRAIL: New Insights in the Treatment of Autoimmune Disorders
Recent Patents on Inflammation & Allergy Drug Discovery Genetic Variation in SLCO2B1 is Associated with Serum Levels of Testosterone and its Metabolites Prior to and Two Days after Testosterone Administration
Current Pharmacogenomics and Personalized Medicine Regulatory T Cells and Skin Tumors
Recent Patents on Inflammation & Allergy Drug Discovery Nano Anti-Cancer Drugs: Pros and Cons and Future Perspectives
Current Cancer Drug Targets A Facile and Green Synthesis of Novel Imide and Amidic Acid Derivatives of Phenacetin as Potential Analgesic and Anti-Pyretic Agents
Letters in Organic Chemistry Anti-Angiogenesis and RGD-Containing Snake Venom Disintegrins
Current Pharmaceutical Design Immunotherapy of Pancreatic Carcinoma
Reviews on Recent Clinical Trials Polyphenolic Compounds: Interactions with the Gut and Implications for Human Health
Current Medicinal Chemistry Lipid-based siRNA Delivery Systems: Challenges, Promises and Solutions Along the Long Journey
Current Pharmaceutical Biotechnology Immunonutrition in Surgical Patients
Current Drug Targets Dual Inhibition of PI3-Kinase and mTOR in Renal Cell Carcinoma
Current Cancer Drug Targets Lipid, Sugar and Liposaccharide Based Delivery Systems 2
Current Medicinal Chemistry Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery The Use of Small Peptides in the Diagnosis and Treatment of Hepatocellular Carcinoma
Protein & Peptide Letters In Silico Structure Modeling and Molecular Docking Analysis of Phosphoribosyl Pyrophosphate Amidotransferase (PPAT) with Antifolate Inhibitors
Current Cancer Drug Targets Oncolytic Virus: Regulatory Aspects from Quality Control to Clinical Studies
Current Cancer Drug Targets Cytopathological Mechanisms in Mitochondrial Disease
Current Chemical Biology Engineered E. coli as Vehicles for Targeted Therapeutics
Current Gene Therapy





